Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Orchard Healthcare Research Inc.
mi
from
Skokie, IL
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Orchard Healthcare Research Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Midwestern Regional Medical Center
mi
from
Zion, IL
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Cancer Care of Louisiana
mi
from
New Orleans, LA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Cancer Care of Louisiana
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Henry Ford Health System
mi
from
Detroit, MI
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Montefiore-Einstein Cancer Center
mi
from
Bronx, NY
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Montefiore-Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Weill Cornell Breast Center/Weill Cornell Medical College
mi
from
New York, NY
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Weill Cornell Breast Center/Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Levine Cancer Institute - Blumenthal Cancer Center
mi
from
Charlotte, NC
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Levine Cancer Institute - Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Center for Biomedical Research
mi
from
Knoxville, TN
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Center for Biomedical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Sarah Cannon Research Institution
mi
from
Nashville, TN
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Sarah Cannon Research Institution
mi
from
Nashville, TN
Click here to add this to my saved trials
Non-Invasive Imaging for Cording in Breast Cancer Patients
Evaluation of Non Invasive Imaging for Assessing the Pathophysiology of Cording in Patients Treated for Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Non-Invasive Imaging for Cording in Breast Cancer Patients
Evaluation of Non Invasive Imaging for Assessing the Pathophysiology of Cording in Patients Treated for Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response
Status: Enrolling
Updated:  3/14/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response
Status: Enrolling
Updated: 3/14/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant
The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant
The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Molecular Breast Imaging in Women With Atypia and LCIS
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Enrolling
Updated:  3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Molecular Breast Imaging in Women With Atypia and LCIS
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Enrolling
Updated: 3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer
A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers
Status: Enrolling
Updated:  3/17/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer
A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers
Status: Enrolling
Updated: 3/17/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Columbia University
mi
from
New York, NY
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Memorial Cancer Center
mi
from
Hollywood, FL
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Memorial Cancer Center
mi
from
Hollywood, FL
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Woodlands Medical Specialists
mi
from
Pensacola, FL
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Woodlands Medical Specialists
mi
from
Pensacola, FL
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Florida Cancer Specialists-East
mi
from
West Palm Beach, FL
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Florida Cancer Specialists-East
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Hope Cancer Center
mi
from
Terre Haute, IN
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Hope Cancer Center
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated:  3/17/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Status: Enrolling
Updated: 3/17/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox™) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer
Status: Enrolling
Updated:  3/18/2016
Duke Cancer Institute
mi
from
Durham, NC
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox™) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer
Status: Enrolling
Updated: 3/18/2016
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated:  3/18/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated: 3/18/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated:  3/18/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated: 3/18/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated:  3/18/2016
University of Colorado
mi
from
Denver, CO
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated: 3/18/2016
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated:  3/18/2016
Newton-Wellesley Hospital
mi
from
Newton, MA
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Status: Enrolling
Updated: 3/18/2016
Newton-Wellesley Hospital
mi
from
Newton, MA
Click here to add this to my saved trials
Effect of Radiation on Tissue for Delayed Breast Reconstruction
Effect of Radiation on Tissue for Delayed Breast Reconstruction
Status: Enrolling
Updated:  3/18/2016
University of Michigan
mi
from
Ann Arbor, MI
Effect of Radiation on Tissue for Delayed Breast Reconstruction
Effect of Radiation on Tissue for Delayed Breast Reconstruction
Status: Enrolling
Updated: 3/18/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Northern Arizona Hematology/Oncology Associates, P.C.
mi
from
Flagstaff, AZ
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Northern Arizona Hematology/Oncology Associates, P.C.
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Oncology & Hematology Associates, PC
mi
from
New London, CT
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Oncology & Hematology Associates, PC
mi
from
New London, CT
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Florida Cancer Specialists, Site #180
mi
from
Fort Meyers, FL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Florida Cancer Specialists, Site #180
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Sarah Cannon Research Institute
mi
from
Jacksonville, FL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Sarah Cannon Research Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Cancer Centers of Florida
mi
from
Ocoee, FL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Florida Cancer Institute
mi
from
Orlando, FL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Florida Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Gulfcoast Oncology Associates
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
University Cancer and Blood Center LLC
mi
from
Athens, GA
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Wichita Community Clinical Oncology Program
mi
from
Wichita, KA
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Wichita Community Clinical Oncology Program
mi
from
Wichita, KA
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
St. Louis Cancer & Breast Institute
mi
from
St. Louis, MO
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
St. Louis Cancer & Breast Institute
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
New York Oncology Hematology, P.C. NYOH Latham
mi
from
Troy, NY
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
New York Oncology Hematology, P.C. NYOH Latham
mi
from
Troy, NY
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Raleigh Hematology Oncology Associates
mi
from
Cary, NC
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Raleigh Hematology Oncology Associates
mi
from
Cary, NC
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Aultman Cancer Center
mi
from
Canton, OH
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Aultman Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Sarah Cannon Oncology Hematology Care, Inc
mi
from
Cincinnati, OH
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Sarah Cannon Oncology Hematology Care, Inc
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated:  3/20/2016
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Status: Enrolling
Updated: 3/20/2016
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
Click here to add this to my saved trials